Immunotherapy trial for relapsed neuroblastoma or osteosarcoma
Part of Cancer clinical trials.
This Phase 1 study tests lab-made donor immune cells (gamma delta T cells) plus chemotherapy to treat neuroblastoma or osteosarcoma that has come back or hasn’t responded to standard treatment. It’s designed to find a safe way to give this treatment and to see how well it might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 months old when you join the study.
- You must have confirmed neuroblastoma/ganglioneuroblastoma or osteosarcoma based on past test results (tumor/bone sample findings).
- Your cancer must be measurable/evaluable and has to be relapsed, progressive, or not responding to standard treatment.
- You must be well enough to take treatment (Lansky score ≥50 if age 16 or under, or Karnofsky score ≥50 if older).
- You must have recovered from side effects of past chemo, immunotherapy, or radiation before starting this study.
- You must meet basic blood, kidney, liver, heart, and breathing requirements, and have no uncontrolled infection at enrollment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a targeted drug called dinutuximab to standard chemotherapy, surgery, and a stem cell transplant for children and young adults with a new diagnosis of high-risk neuroblastoma. The goal is to see if this combination helps more patients stay in remission.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This Phase 1 study tests an experimental CAR T-cell treatment that targets GD2, with added immune-boosting and safety features, for children with relapsed or refractory neuroblastoma or osteosarcoma. It’s designed to see if the treatment is safe and can shrink these cancers when standard therapy hasn’t worked.
This early-phase study tests whether giving donated NK cells with three medicines can shrink neuroblastoma that has come back or not responded well to prior treatment. It’s designed for people who have limited options, and the goal is to see safety and whether the combination works.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy (temozolomide and irinotecan), natural killer cells (NK cells), and an antibody therapy (GD2 mAb) to see if it can help children and young adults with high-risk neuroblastoma that has not responded to treatment or has come back.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.